Search

News

New EU In Vitro Diagnostic medical devices Regulation (IVDR) comes into effect

On May 26, 2022, the new EU In Vitro Diagnostic medical devices Regulation (IVDR) came into effect, mandating stricter and more comprehensive certification and testing protocols for in vitro…

Read more

EHA welcomes European Parliament backing for SoHO legislation

EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.

Read more

Guidelines Committee

Current committee members
Carlo Dufour, Italy (Chair)
Martin Dreyling, Germany (Vice-Chair)
Steffen Koschmieder, Germany (Executive member)
Marieke Kruip, The Netherlands (Executive member)
Area associate members
Tamam Bakchoul, Germany
Sabine Blum, Switzerland 
Cristina Castilla Llorente, France 
Lydie Da Costa, France
Wojciech Jurczak, Poland
Noémi Roy, United Kingdom
Giovanna Russo, Italy
Cynthia So-Osman, The Netherlands
AimThe…

Read more

EHA Taskforce on Diversity, Equity, and Inclusion

The Diversity, Equity, and Inclusion Taskforce has a mandate from the EHA Board to develop a policy on Diversity, Equity, and Inclusion that will be the blueprint for:

Initiating and implementing activities to empower underrepresented groups.

Read more

Clinical Practice Guidelines

EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more